In the Rivaroxaban Once Daily , Oral , Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation ( ROCKET AF ) , a randomized , double-blind , double-dummy study of rivaroxaban and warfarin in nonvalvular atrial fibrillation , baseline characteristics , management , and outcomes , including stroke , non-central nervous system systemic embolism , death , myocardial infarction , and bleeding , were reported in participants who experienced TI ( 3-30 days ) for any reason .